Read around the subject

Andrew Huberman, PhD, neuroscientist and tenured professor at Stanford School of Medicine.

'Peptides: The Science, Uses & Safety | Dr. Abud Bakri' (Jun 2026), covering BPC-157, TB-500, GHK-Cu, GLP-1s and retatrutide, and GH secretagogues; also 'Dr. Craig Koniver: Peptide & Hormone Therapies' (Oct 2024).

Peter Attia, MD (Stanford MD, Johns Hopkins surgical training), longevity physician, author of Outlive.

The Drive #403 'Peptides: separating scientific promise from marketing hype' (Aug 2026), an evidence framework applied to BPC-157 and CJC-1295; also AMA #64 on GLP-1 agonists.

Science-animation studio known for heavily researched, sourced explainers.

'The Uncomfortable Truth About Ozempic (Updated Version)', an animated explainer of how GLP-1 drugs work and what they trade off.

Nick Norwitz, MD (Harvard) and PhD (Oxford), metabolic-health researcher and educator.

'The Science Behind Ozempic & Other GLP-1 Medications', an explainer of incretin biology.

Brad Stanfield, MD, primary care physician in New Zealand who covers preventive medicine and longevity evidence.

'Did the FDA Just Approve BPC-157?' (originally titled 'Why Is BPC-157 Banned If It Doesn't Work?'), which reviews the evidence and regulatory status of BPC-157.

Rena Malik, MD, board-certified urologist and pelvic surgeon.

Podcast videos 'BPC-157: Miracle Healing Peptide or Dangerous Gamble?' (Aug 2026, covering BPC-157, CJC-1295 and GLP-1s) and 'Can Peptides Heal Your Joints, Gut, and Brain? Doctors Explain the Evidence' (Feb 2026).

Mikhail Varshavski, DO, board-certified family medicine physician in New York City.

'Exposing the Truth About Peptides' (Sep 2026, also published by MedPage Today), covering what peptides are, the gray market, and the FDA compounding committee review of BPC-157 and TB-500.

Spencer Nadolsky, DO, board-certified family physician specializing in obesity medicine and lipidology; co-host of Docs Who Lift.

'Ozempic Kids Are Here (Obesity Doctor Reacts)', plus Docs Who Lift episodes on retatrutide phase 3 data and GLP-1 maintenance.

Jordan Feigenbaum, MD, and Austin Baraki, MD, physicians who combine medicine and strength training.

Podcast Ep. 377 'GLP-1 Anti-Obesity Medications Update: Efficacy, Muscle Risk and Future' (Dec 2025); also a guest on Docs Who Lift's 'Are Peptides the New Snake Oil?'

Gabrielle Lyon, DO, board-certified family physician and founder of Muscle-Centric Medicine.

'The Science of Optimal Hormone Health | Dr. Melanie Cree' (Ep. 149, Apr 2025), with a pediatric endocrinologist on GLP-1s and semaglutide in PCOS and metabolic health.

Jason Fung, MD, nephrologist and author of The Obesity Code and The Diabetes Code.

'5 ways to naturally boost the Ozempic Effect', which explains the GLP-1 and incretin mechanism.

Medical-education channel taught by Professor Zach Murphy for health-professions students.

'Endocrinology | Growth Hormone', a whiteboard lecture on GH release and its stimuli, the physiology behind GH secretagogues.

Free educational video series (Complexly/PBS Digital Studios) used widely in classrooms.

'Endocrine System, Part 1 - Glands & Hormones: Crash Course Anatomy & Physiology #23', which explains amino-acid-based (peptide) versus steroid hormones.

PBS's flagship science series, produced by GBH Boston since 1974.

'Ozempic's Surprising Real Power' (Aug 2024), on new evidence that GLP-1 drugs act on the brain as well as the gut.

Nicolas Verhoeven, PhD in Molecular Medicine (cell physiology), MS in exercise physiology; reviews many studies per topic.

'This Peptide will Revolutionize Health!', plus multi-study breakdowns of retatrutide, tirzepatide versus semaglutide, and GLP-1 muscle-loss data.

Layne Norton, PhD in nutritional sciences, evidence-based nutrition and physique coach.

'Weight Loss Medications: Great for Losing Weight, But Not for Keeping It Off?', on GLP-1 drugs and weight regain.

Matt Kaeberlein, PhD, biology-of-aging researcher and former University of Washington professor.

'RFK Jr and Joe Rogan's Peptide Claims: Longevity Expert Reacts' (Mar 2026), fact-checking claims about BPC-157, GLP-1s and the FDA Category 2 list.

Medical education studio (part of Elsevier) used by medical and nursing students.

Short illustrated explainers on hormones, receptors, the pituitary and pancreas, and how drugs are tested.

Armando Hasudungan, medical illustrator and physician known for hand-drawn physiology lessons.

Hand-drawn walkthroughs of endocrine physiology, including the growth hormone axis, insulin and glucagon.

Khan Academy's free health and medicine channel.

Beginner-friendly lessons on amino acids, proteins, hormones and receptor signaling.

Cadaver-based anatomy lab and education channel founded in 2012 by Jeremy Jones and Jonathan Bennion.

'What Ozempic & Weight Loss Drugs Really Do to the Body' (Mar 2025), on how GLP-1 receptor agonists work, how well they work and their safety.

Video channel of the journal Science (AAAS).

'How weight loss drugs like Ozempic offer benefits beyond the scale' (Dec 2023), on the decades of research behind GLP-1 drugs, Science's 2023 Breakthrough of the Year.

Harvard Medical School's continuing-education channel for health care professionals.

'Role of GLP-1 Receptor Agonists for Weight Loss' (May 2022), in which Brigham and Women's endocrinologist Lee-Shing Chang, MD, compares liraglutide and semaglutide using the SCALE and STEP trials.

Medical animation studio in Kennesaw, Georgia.

'How Semaglutide Works in Weight Loss and Type 2 Diabetes' (Jul 2025), a short animation of how semaglutide mimics GLP-1, plus common side effects.

Medical animation studio making short mini-lectures for students and patient education.

'Semaglutide (Ozempic, Wegovy, Rybelsus) - Mechanisms of Action and Pharmacology, Animation' (Dec 2025), including why its structural changes make it last longer in the body than natural GLP-1.

Science explainer channel hosted by Hank Green and team (Complexly).

'Ozempic Is Both Better And Worse Than You Think' (Nov 2025), on lesser-known upsides and downsides of semaglutide.

Explanatory journalism outlet with a large video team.

'Ozempic is a game-changer. Here's how it works.' (Mar 2023), on how semaglutide mimics the gut hormone GLP-1 to affect blood sugar, digestion and appetite.

Official channel of the nonprofit Mayo Clinic academic medical center.

'Stopping GLP-1s: How to avoid weight regain | Mayo Clinic On Nutrition Podcast' (Oct 2026), with dietitian Tara Schmidt and weight-management researcher James O. Hill.

Official channel of the nonprofit Cleveland Clinic academic medical center.

'Answering Your Questions About GLP-1s | Keren Zhou, MD' (Nov 2025), an endocrinologist on safety, side effects, long-term use and who may be a candidate.

Official channel of Stanford Health Care, Stanford Medicine's hospital system.

'GLP-1 Receptor Agonists: The Truth Behind the Trend' (Feb 2025), a talk by clinical pharmacist Michael Blyumin, PharmD, on FDA-approved GLP-1 drugs, their benefits and risks, and what happens when people stop them.

Professional society of about 18,000 hormone researchers and endocrinologists.

'Beyond the Needle: The Future of GLP-1 Pills and Other Emerging Obesity Treatments' (Dec 2025), on oral GLP-1s and multi-agonists in trials (the event was supported by Eli Lilly, as the description notes).

Hosted by Andrew Huberman, PhD

'Peptides: The Science, Uses & Safety | Dr. Abud Bakri' (Jun 1, 2026), covering BPC-157, TB-500, GHK-Cu, epitalon, GLP-1s, thymosin alpha-1, tesamorelin, ipamorelin and MK-677.

Hosted by Peter Attia, MD

#403 'Peptides: separating scientific promise from marketing hype' (Aug 10, 2026), with BPC-157 and CJC-1295 as case studies and tesamorelin, SS-31 and retatrutide for comparison.

Hosted by Rena Malik, MD

'BPC-157: Miracle Healing Peptide or Dangerous Gamble?' (Aug 21, 2026), with Drs. Mohit Khera, Kevin Campbell and Alex Tatem on BPC-157, CJC-1295, GLP-1s and regulation.

Hosted by Spencer Nadolsky, DO & Karl Nadolsky, MD

'Are Peptides the New Snake Oil? What the Actual Science Says With Barbell Medicine' (Jun 2026) and 'Retatrutide Phase 3 Results: What the Data Actually Means'.

Hosted by Eric Topol, MD

'Daniel Drucker: Illuminating the GLP-1 Drug's Break Out' (Apr 2024), with a co-discoverer of GLP-1 on its biology, side effects and dual/triple agonists.

Hosted by Danny Lennon

#582 'GLP-1 Agonists: Side Effects, Management and Diet' with obesity-medicine physician Dr. Spencer Nadolsky.

Hosted by Matt Kaeberlein, PhD

'RFK Jr and Joe Rogan's Peptide Claims: Longevity Expert Reacts' (Mar 7, 2026), on BPC-157, GLP-1s, compounding and the FDA Category 2 list.

Hosted by Wendy Zukerman

'Weight Loss Meds: Is Ozempic a Miracle Drug?' (Mar 2023), on GLP-1 trial results, mechanism and side effects; also 'Collagen Peptides: Should You Take Them?'

Hosted by STAT News biotech reporters

Weekly biotech and pharma news, including obesity-drug trials, FDA decisions and how drugs move through approval.

Hosted by Nature journal editors

Weekly stories on new research from the journal Nature, useful for learning how scientists describe findings.

Hosted by Rachel Feltman (Scientific American)

'"Wolverine" stack, "peptide parties," "biohacking": Is the peptide craze backed by science?' (2026), with The Verge's Victoria Song on gray-market peptides, proposed FDA changes and the limited evidence.

Hosted by Callam Davidson and Miriam Sabin (Lancet editors)

'The next generation of weight-loss drugs' (Jul 2025), with Steven Heymsfield of Pennington Biomedical on semaglutide, tirzepatide, muscle preservation and long-term safety questions.

Hosted by Meghna Chakrabarti (WBUR)

'The science behind GLP-1s' (Jul 6, 2026), with Jens Juul Holst, a University of Copenhagen scientist who helped discover the GLP-1 hormone.

Hosted by JAMA editors

'Obesity Medications', in which JAMA Deputy Editor Mary McGrae McDermott, MD, interviews Robert F. Kushner, MD, of Northwestern on how newer weight-loss drugs are used.

Hosted by Darryl S. Chutka, MD

'Rx for Weight Loss: A Closer Look Series: Who Is a Candidate for a GLP-1 Medication?' (Jan 2026), with Mayo endocrinologists Tamim Rajjo, MD, and Meera Shah, MB ChB.

Hosted by Matthew Watto, MD & Paul Williams, MD

#405 'Obesity Medicine, GLP1 agonists, Weight Loss Management Tools and Tips' (Jul 2023), with Kimberly Gudzune, MD, MPH, on obesity as a chronic disease.

Hosted by Mic Cavazzini (Royal Australasian College of Physicians)

Ep102 'Staying on script with semaglutide' (Nov 2023), with Profs. Chris Rayner and Gary Wittert on GLP-1 drugs, shortages and concerns about compounded semaglutide.

Hosted by Stephen J. Dubner

#615 'Is Ozempic as Magical as It Sounds?' (Dec 2024), with physician and ethicist Ezekiel Emanuel on GLP-1 benefits, side effects and open questions.

Hosted by Christopher Labos, MD, with co-hosts

A cardiologist-led show, running since 2015, that checks health headlines against the evidence; recent episodes include 'The Health and Wellness Lie' (Oct 2026) and 'PCOS Is Now PMOS: The Controversy Behind the Name Change' (Aug 2026).

Find the original studies behind any peptide claim; filter by 'Clinical Trial' or 'Humans' to tell animal-only evidence (most of BPC-157) from human data.

Check whether a peptide has registered human trials, their phase, status and results (e.g., retatrutide, tesamorelin, BPC-157).

Look up a compound's identity: sequence and structure, molecular weight, synonyms and CAS numbers, safety data, and linked literature and patents.

See the natural parent protein or hormone a peptide comes from (e.g., GLP-1 from proglucagon, GHRH, thymosin beta-4), with its sequence and function.

Primary source for FDA briefing documents and votes on peptides proposed for the 503A bulks list (Jul 2026 meeting: BPC-157, KPV, TB-500, MOTS-c, emideltide, epitalon, semax).

Check whether a peptide is banned in sport (S0 non-approved substances, e.g., BPC-157; S2 peptide hormones, growth factors and GH secretagogues), a common buyer question.

Read the official labels of FDA-approved peptide drugs (semaglutide, tirzepatide, tesamorelin, bremelanotide) to see what each branded drug is approved for, which research materials are not.

A free alternative to PubMed with millions of full-text articles, handy for reading a whole paper rather than only the abstract.

Systematic reviews and a register of controlled trials, the top of the evidence pyramid; check whether a review exists before trusting a single study.

Free, peer-reviewed clinical reference articles on drugs, hormones and conditions (e.g., GLP-1 agonists, growth hormone), written for clinicians and students.

The European Medicines Agency's medicine finder, including refused and withdrawn products, to compare EU and US approval status.

Explains FDA's Category 1, 2 and 3 system for substances nominated for compounding, the framework behind most peptide regulation news.

FDA's Category 2 table (e.g., GHRP-2, GHRP-6, ipamorelin, kisspeptin-10) and its list of withdrawn nominations (e.g., BPC-157, TB-500, CJC-1295); check the 'content current as of' date, since it changes.

FDA's own statement on compounded and 'research use only' semaglutide, tirzepatide and retatrutide, including salt forms and adverse-event reports.

Searchable record of FDA warning letters, useful for seeing how FDA acts against sellers of unapproved peptide products and against quality failures.

3D structures of proteins and peptides, plus beginner PDB-101 lessons, to see what a peptide and its receptor actually look like.

Health and medicine reporting on GLP-1 drugs, trials and FDA decisions; some stories are behind the STAT+ paywall.

Biotech and pharma industry news with topic hubs on GLP-1 drugs and FDA policy; useful for following obesity-drug pipelines.

Pharma industry news on manufacturing, marketing and regulation, including an oral GLP-1 tracker.

The primary source for FDA approvals, enforcement actions and policy changes; read this before relying on secondhand reports.

Daily regulatory news from the Regulatory Affairs Professionals Society, including FDA advisory committee and warning letter coverage.

University science-communication office that separates sense from nonsense; see 'BPC-157 – No Proof Required!' (Mar 2026) by GLP-1 researcher Patricia Brubaker, PhD.

Physician-edited blog (Steven Novella, David Gorski) that examines health claims, wellness trends and regulatory news against the evidence.

Khan Academy

Free, beginner-level primer on how hormones (including peptide hormones like insulin) signal through the body.

Duke University (Coursera)

Endocrine modules on the hypothalamus-pituitary axis (growth hormone, stress, thyroid) and pancreatic control of metabolism; free to enroll.

HarvardX (edX / Harvard Online)

Self-paced course on amino acids, protein structure, enzymes and drug interactions, the chemistry behind what a peptide is; free to audit (the certificate is optional and paid).

UC San Diego Skaggs School of Pharmacy (Coursera)

Explains the preclinical-to-IND pipeline, so partners understand why 'research use only' peptides are not approved drugs.

Yale University (Coursera)

Teaches study design, statistics and bias so partners can judge peptide claims and studies themselves.

National Institutes of Health (NIH OCRECO)

Free, self-paced NIH course (about 40 recorded lectures) on study design, biostatistics, ethics and regulation; the 2026-2027 session runs Sep 2026 to Jul 2027.

U.S. Food and Drug Administration

Free FDA modules, including 'Regulatory Framework for Human Drug Compounding' (503A versus 503B) and 'Sterility Testing: Common Misconceptions', the basics of compounding law and quality.

Johns Hopkins University (Coursera)

Covers trial designs, randomization, blinding, outcomes and CONSORT reporting, so partners can tell a strong human trial from a weak one; free to enroll, certificate paid.

MIT OpenCourseWare

Free, self-study course with lecture videos on biochemistry, molecular biology and genetics, the foundation for understanding how peptides are made and act.

MIT OpenCourseWare (Harvard-MIT Health Sciences and Technology)

Free graduate-level notes on dose-response, pharmacokinetics, drug delivery, interactions and toxicity; best for partners who want depth.

The Open University (OpenLearn)

Free two-hour course on how a candidate molecule becomes an approved medicine, using pain drugs as the example.

How to Read a Paper: The Basics of Evidence-Based Healthcare (7th ed.)

Trisha Greenhalgh

The standard plain-English guide to judging a medical study, from trial types to bias to statistics.

Hormones: A Very Short Introduction

Martin Luck

A short, readable overview of hormone types (peptide versus steroid), receptors and feedback loops.

The Discovery of Insulin

Michael Bliss

The history of the first peptide drug, from lab to clinic to manufacturing, which explains why purity, manufacturing and regulation matter.

Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight-Loss Drugs

Johann Hari

An accessible, balanced journalistic look at GLP-1 drugs (Ozempic, Wegovy, Mounjaro), the peptides research buyers ask about most.

Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients

Ben Goldacre

Shows how evidence gets distorted by industry, useful for spotting overclaiming in peptide marketing.

Off the Scales: The Inside Story of Ozempic and the Race to Cure Obesity

Aimee Donnellan

A Reuters journalist's 2025 history of GLP-1 drug discovery and development, including the peptide chemistry behind semaglutide.

Diet, Drugs and Dopamine: The New Science of Achieving a Healthy Weight

David Kessler

A former FDA commissioner's 2025 book on how GLP-1 drugs act on appetite and why they work best with other support.

Bad Science

Ben Goldacre

A readable tour of how health claims go wrong, from placebo effects to media misreporting; a companion to Bad Pharma.

Rigor Mortis: How Sloppy Science Creates Worthless Cures, Crushes Hope, and Wastes Billions

Richard Harris

An NPR science reporter on why many lab and animal findings fail to replicate, which matters for peptides supported mostly by preclinical data.

Ending Medical Reversal: Improving Outcomes, Saving Lives

Vinayak K. Prasad and Adam S. Cifu

Shows how accepted treatments are later found not to work, and why proof should come before practice.

Testing Treatments: Better Research for Better Healthcare (2nd ed.)

Imogen Evans, Hazel Thornton, Iain Chalmers and Paul Glasziou

A plain-language guide to fair tests of treatments, free to read online at testingtreatments.org.

Bottle of Lies: The Inside Story of the Generic Drug Boom

Katherine Eban

Investigative account of data fraud and manufacturing shortcuts in drug production, which shows why independent quality testing matters.

Outlive: The Science and Art of Longevity

Peter Attia with Bill Gifford

A general longevity book on exercise, nutrition, sleep and chronic disease; it is not about peptides, but it gives context for the longevity conversations buyers raise.

Ageless: The New Science of Getting Older Without Getting Old

Andrew Steele

A survey of the biology of aging, from senescent cells to lifespan studies in animals, useful background for longevity and bioregulator claims.